In California, synthetic biology firm Amyris has sold three ingredients to beauty and fragrance major Givaudan. The products sold include performant emollient Neossance® Squalane; plant-based silicone alternative Neossance® Hemisqualane; and sun protector CleanScreen. Givaudan and Amyris also signed a long-term partnership agreement under which Amyris will continue to manufacture ingredients for Givaudan to use in […]
In California, renewable chemical maker Amyris, Inc. has entered into a definitive purchase agreement for stock and announced a concurrent private placement, saying the combination will net about $50 million. The funds will be used for general corporate purposes. The definitive purchase agreement covers the purchase and sale of 20,000,000 shares of the Company’s common […]
In California, Amyris, Inc. has completed the negotiation of key financial and business terms of the previously communicated strategic transaction for the exclusive rights to supply two of Amyris’ ingredients. The transaction is subject to antitrust review under the Hart-Scott-Rodino Act (“HSR”) with a standard waiting period of thirty days. Accordingly, the transaction is expected […]
In Brazil, Amyris, Inc. has successfully started fermentation at its new precision fermentation plant in Barra Bonita, Brazil. The greenfield site at Barra Bonita establishes Amyris as the leading manufacturer of highly engineered organisms at industrial scale. The first of its kind precision fermentation plant is a strategic investment made to meet rapidly growing demand […]
It’s only the second month of 2022, but there are already many people on the move from some of The Digest’s Hot 50 companies and leading biofuels and biotech organizations. From a new Chief Commercial Officer at Topsoe, the shifting of Ron Lamberty’s role from SVP and Market Development Director to Chief Marketing Officer at […]
In California, Amyris, Inc. completed a previously announced joint venture agreement with MF 92 VENTURES LLC, a Minerva Foods subsidiary, to develop molecules for the sustainable production and distribution of animal protein. Minerva and Amyris will collaborate on the development, scale-up and production of new target molecules, which Minerva will fund and bring to market […]
It was as busy as a mosh pit, as coordinated and fluid as Astaire and Rogers — the penny dropped on what the Unites States of America plans to do about sustainable aviation fuels, with more than a dozen companies and government agencies in the mix, as US airlines agreed to reach 3 billion […]
In California, Amyris, Inc. achieved promising in-vivo results in a study of its licensed RNA vaccine through intranasal delivery, developed in collaboration with the Infectious Disease Research Institute (IDRI), which means an effective Covid-19 nose spray vaccine could become reality. In-vivo results indicate that, when delivered to the mucosal membranes via intranasal administration, the Amyris/IDRI […]
In California, Amyris, Inc. reports another record quarter of underlying revenue, another record quarter of consumer revenue and significant gross margin expansion, and a strong cash position and robust outlook into second half 2021. “With Q2 we completed another quarter of strong strategic and operational execution,” said John Melo, President and Chief Executive Officer. “We […]
In California, Amyris, Inc. signed an exclusive license with Nant Africa, LLC relating to the development and use of the RNA COVID vaccine Amyris developed in coordination with the Infectious Disease Research Institute (IDRI). Amyris’ partnership with Nant Africa is of significant value to Amyris as it provides the fastest path to market for the […]
